PDCD1 and hepatocellular carcinoma: In order to further explain the excellent therapeutic effect of meloxicam combined with PD1 monoclonal antibody on mouse HCC models, we discovered through a series of experiments that COX2 can interact with microRNA-200 to cause changes in PD-L1 levels.